Unraveling the Therapeutic Role of Myoinositol in Polycystic Ovary Syndrome

Malak Shariff, Dr. Mamta Saraf, Valanka Melicia Fernandes, Zoya Sadaf, Bhalavikashini D R, Sai Krishna Mohana Kondra, Rohan K and Samuel Bilgates Brettlee
Additional contact information
Malak Shariff: Department of Cardiac Care Technology, Jain University, Bengaluru, Karnataka, India
Dr. Mamta Saraf: Department of Clinical Diagnostics, Jain University, Aurangabad, Maharashtra, India
Valanka Melicia Fernandes: Department of Psychology, Jain University, Shiroda, Goa, India
Zoya Sadaf: Department of Psychology, Jain University, Ramnagar, Karnataka, Indi
Bhalavikashini D R: Department of Psychology, Jain University, Bengaluru, Karnataka, India
Sai Krishna Mohana Kondra: Department of Psychology, Jain University, Rajamahendravaram, Andhra Pradesh, India
Rohan K: Department of Cardiac Care Technology, Jain University, Bengaluru, Karnataka, India
Samuel Bilgates Brettlee: Department of Psychology, Jain University, Bengaluru, Karnataka, India

International Journal of Research and Scientific Innovation, 2025, vol. 12, issue 4, 1360-1373

Abstract: Polycystic ovary syndrome (PCOS) is a multifaceted endocrine disorder affecting a significant number of women of reproductive age. It is characterized by irregular menstrual cycles, hyperandrogenism, and polycystic ovaries, contributing to infertility and metabolic disturbances. Inositol, particularly myo-inositol (MI), has emerged as a promising therapeutic approach for managing PCOS symptoms. Myo-inositol is an essential component of cell membranes and a precursor to several important signaling pathways. Recent studies have highlighted its beneficial effects on insulin sensitivity, ovarian function, and hormonal regulation in women with PCOS. This review states the potential mechanisms through which myo-inositol modulates insulin resistance, a key metabolic feature of PCOS, and its impact on ovarian function, including its role in improving oocyte quality and promoting regular menstrual cycles. Furthermore, the combination of myo-inositol with D-chiro-inositol (DCI) has been studied for its synergistic effects in managing PCOS symptoms. By evaluating the current literature, this review provides insights into the clinical efficacy of myo-inositol as a safe and effective adjunct in the management of PCOS, with particular emphasis on its role in restoring metabolic balance and improving reproductive outcomes. The review also discusses the challenges and areas for future research to further elucidate the optimal dosing, treatment regimens, and long-term outcomes of myo-inositol therapy for PCOS.

Date: 2025
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.rsisinternational.org/journals/ijrsi/d ... ssue-4/1360-1373.pdf (application/pdf)
https://rsisinternational.org/journals/ijrsi/artic ... stic-ovary-syndrome/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bjc:journl:v:12:y:2025:i:4:p:1360-1373

Access Statistics for this article

International Journal of Research and Scientific Innovation is currently edited by Dr. Renu Malsaria

More articles in International Journal of Research and Scientific Innovation from International Journal of Research and Scientific Innovation (IJRSI)
Bibliographic data for series maintained by Dr. Renu Malsaria ().